Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Evaluating the Barrier Function, Regenerative Capacity, and Soft Tissue Outcomes of Acellular Dermal Matrix

21 de mayo de 2026 actualizado por: Maria L. Geisinger, DDS, MS, University of Alabama at Birmingham

A Prospective, Double-Arm, Randomized Controlled Trial Evaluating the Barrier Function, Regenerative Capacity, and Soft Tissue Outcomes of Acellular Dermal Matrix Compared to Resorbable Collagen Membranes in Edentulous Ridge Augmentation

This investigator-initiated study will compare ADM and resorbable cross-linked collagen membrane barriers for guided bone regeneration at atrophic lateral ridge augmentation sites.

Descripción general del estudio

Descripción detallada

This investigator-initiated study will compare ADM and resorbable collagen membrane barrier for guided bone regeneration. Systematic reviews and randomized clinical trials confirm that resorbable collagen membranes combined with particulate graft materials predictably increase horizontal ridge width, typically achieving gains of approximately 3-5 mm at 6 months.3,5 The biologic mechanism involves clot stabilization, space maintenance (often supported with fixation tacks or tenting screws), and exclusion of competing soft tissue cells.3 Despite these predictable outcomes, collagen membranes possess inherent limitations, including limited intrinsic structural rigidity, susceptibility to enzymatic degradation when exposed6 and lack of contribution to gingival phenotype modification.

In contrast, human data evaluating acellular dermal matrix (ADM) as a barrier membrane in horizontal guided bone regeneration is limited. One of the earliest clinical and histologic investigations evaluated ADM in the management of Seibert Class I horizontal ridge defects using particulate grafting and reported both clinical ridge width improvement and histologic evidence of new vital bone formation.12 Notably, the authors also observed increased soft tissue thickness at treated sites, suggesting a potential dual hard- and soft-tissue benefit for its use. However, this study was a single-arm design without a direct comparator group, limiting the ability to determine whether outcomes were equivalent or superior to those achieved with conventional collagen membranes.

The majority of human ADM literature focuses on periodontal plastic surgery applications rather than GBR, including tooth root coverage procedures to treat gingival recession,10 peri-implant soft tissue augmentation,15 and keratinized tissue (KT) augmentation techniques.16 These investigations consistently demonstrate increased mucosal thickness and KT width with ADM use, reinforcing its soft tissue regenerative capacity. Nevertheless, these outcomes cannot be extrapolated directly to horizontal ridge augmentation without controlled comparative data.

Preclinical animal studies provide additional biologic rationale. It has been demonstrated in a canine GBR model that ADM functioned as an effective barrier membrane, with histologic evidence of new bone formation comparable to bioabsorbable membranes.17 Additional animal studies have shown that ADM supports vascular infiltration, integrates into host tissues, and maintains an acceptable inflammatory profile during early healing.18 Histomorphometric analyses in these models report woven bone formation beneath ADM at early intervals, followed by progressive remodeling into lamellar bone. While these findings support the biologic plausibility of ADM as a GBR membrane, animal data cannot substitute for controlled human clinical trials.16-19 Importantly, no adequately powered human randomized controlled trial has directly compared ADM and resorbable cross-linked collagen membranes head-to-head in horizontal ridge augmentation with GBR using standardized volumetric CBCT analysis, histomorphometric evaluation of post-healing bone biopsy, and longitudinal soft tissue assessment. Existing studies either evaluate collagen membranes alone,3,5 assess ADM in non-comparative design,12 or evaluate ADM and other autogenous, xenogeneic, or allogeneic soft tissue grafts for phenotype modification without simultaneous GBR.10,14,15 Consequently, it remains unclear whether ADM provides equivalent bone volume augmentation, histologic bone formation, and if it confers additional soft tissue benefits in the context of ridge augmentation, or whether its clinical performance differs in the setting of membrane exposure.

This absence of direct comparative human data represents a critical gap in the literature and provides the rationale for a randomized controlled trial evaluating ADM versus resorbable collagen membranes in horizontal guided bone regeneration.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

70

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Sarah Startley, DMD
  • Número de teléfono: 205-975-8711
  • Correo electrónico: ss1971@uab.edu

Copia de seguridad de contactos de estudio

  • Nombre: Maria Geisinger, DDS, MS
  • Número de teléfono: 205-934-4984
  • Correo electrónico: miagdds@uab.edu

Ubicaciones de estudio

    • Alabama
      • Birmingham, Alabama, Estados Unidos, 35294
        • University of Alabama at Birmingham
        • Contacto:
          • Sarah Startley, DMD
          • Número de teléfono: 205-975-8711
          • Correo electrónico: ss1971@uab.edu
        • Contacto:
          • Maria Geisinger, DDS, MS
          • Número de teléfono: 205-934-4984
          • Correo electrónico: miagdds@uab.edu
        • Investigador principal:
          • Maria Geisinger, DDS, MS

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

Descripción

Inclusion Criteria:

  • English speaking
  • At least 18 years old
  • Must be a patient of the UAB Dental School
  • Able to read and understand informed consent document
  • Patients presenting with a diagnosed need horizontal ridge augmentation with GBR without simultaneous implant placement, to allow for future dental implant placement.
  • Presence of periodontally healthy, non-carious neighboring teeth and/or healthy restored dental implants on either side of the edentulous span planned for GBR, or unhealthy adjacent teeth to be extracted during the same visit.
  • ≤4 mm ridge width in a Seibert Class I Edentulous span19
  • No anticipated need for surgical and/or endodontic care at planned teeth adjacent to the proposed surgical site during the study period.

Exclusion Criteria:

  • Non-English speaking
  • Less than 18 years old
  • Smokers/nicotine users (defined as currently reporting use of any form of tobacco/nicotine products)
  • Patients with systemic pathologies or conditions contraindicating oral surgical procedures or adversely affecting wound healing, including:

    • Uncontrolled diabetes (HbA1c > 7%)
    • Untreated periodontal disease
    • History of head/neck radiation
    • IV bisphosphonates
    • Immunocompromised state
    • Pregnancy
    • Acute infection at site
  • Documented or suspected allergy or sensitivity to any study product

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Guided Bone Regeneration with ADM (AlloDerm) as a barrier
GBR will be performed using a composite particulate graft consisting of a combination of freeze-dried bone allograft (FDBA) and xenograft in a 75%/25% mixture. Following decortication and graft placement to reconstruct the horizontal ridge deficiency, acellular dermal matrix (ADM) will be adapted to fully cover the augmented site with appropriate extension beyond the defect margins. The ADM will be stabilized using titanium tacks and/or periosteal sutures as needed to ensure space maintenance and membrane stability.
GBR will be performed using a composite particulate graft consisting of a combination of freeze-dried bone allograft (FDBA) and xenograft in a 75%/25% mixture. Following decortication and graft placement to reconstruct the horizontal ridge deficiency, acellular dermal matrix (ADM) will be adapted to fully cover the augmented site with appropriate extension beyond the defect margins. The ADM will be stabilized using titanium tacks and/or periosteal sutures as needed to ensure space maintenance and membrane stability.
Comparador activo: Guided Bone Regeneration with Resorbable Crosslinked Collagen Matrix (Mem-Lok) as a barrier
GBR will be performed using a composite particulate graft consisting of a combination of freeze-dried bone allograft (FDBA) and xenograft in a 75%/25% mixture. The graft will be contoured to reconstruct the horizontal ridge deficiency following decortication of the recipient site. A resorbable collagen membrane [Mem-Lok® Resorbable Collagen Matrix (RCM) will be trimmed and positioned to fully cover the grafted area with extension beyond the defect margins and stabilized using titanium tacks and/or periosteal sutures as needed.
GBR will be performed using a composite particulate graft consisting of a combination of freeze-dried bone allograft (FDBA) and xenograft in a 75%/25% mixture. The graft will be contoured to reconstruct the horizontal ridge deficiency following decortication of the recipient site. A resorbable collagen membrane [Mem-Lok® Resorbable Collagen Matrix (RCM) will be trimmed and positioned to fully cover the grafted area with extension beyond the defect margins and stabilized using titanium tacks and/or periosteal sutures as needed.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Horizontal ridge width gain
Periodo de tiempo: baseline to 6 months
Horizontal ridge width gain (mm) at 6 months post-GBR (CBCT-based measurement) at 2mm and 4mm from the alveolar crest
baseline to 6 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Soft tissue thickness change
Periodo de tiempo: 9 months
Clinical assessment using an endodontic reamer and a calibrated periodontal probe
9 months
Patient centered outcomes using the Visual Analog Scale (VAS)
Periodo de tiempo: 4 weeks
Patient centered outcomes including pain, bleeding, swelling, change in daily activities at 2 weeks and 4 weeks postoperatively, using the Visual Analog Scale (VAS)
4 weeks

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Maria L Geisinger, DDS, MS, University of Alabama at Birmingham

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de octubre de 2026

Finalización primaria (Estimado)

1 de octubre de 2027

Finalización del estudio (Estimado)

1 de octubre de 2028

Fechas de registro del estudio

Enviado por primera vez

21 de mayo de 2026

Primero enviado que cumplió con los criterios de control de calidad

21 de mayo de 2026

Publicado por primera vez (Actual)

29 de mayo de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

29 de mayo de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

21 de mayo de 2026

Última verificación

1 de mayo de 2026

Más información

Términos relacionados con este estudio

Palabras clave

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • IRB-300016808
  • UAB Periodontology (Otro identificador: University of Alabama at Birmingham)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

Data from this study will not be shared with other researchers outside of our research team.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir